At the helm of our organization are two seasoned professionals with scientific, business, leadership, and financial acumen. They guide our commitment to excellence and set our path to successfully advance global health.
Dr. Jan Groen joined Intravacc in May 2020 as Chairman and Chief Executive Officer. He was previously the CEO of Novigenix in Switzerland, a privately-owned immunotranscriptomic diagnostic company, and MDxHealth, a Euronext-listed genomic diagnostics company. His career spans many years in the global biotech sector. He was the President and COO of Agendia, co-founder of ViroClinics and DxOrange, and has held management and scientific positions at Focus Diagnostics, the Erasmus Medical Center, the National Institute of Public Health, and Akzo-Nobel. Currently he is the Chairman of the Board of Angle Plc in the UK, and Board member of SPL Medical in Nijmegen, The Netherlands, and Novigenix in Switzerland. He has published over 125 papers in international scientific journals and holds a PhD in Medical Microbiology from Erasmus University Rotterdam.
Nathalie Laarakker joined Intravacc in April 2021 as Chief Financial Officer. She is an experienced CFO and has worked as a finance director for multinational companies. She has a proven track record in financial and senior-level management, primarily in the technology and healthcare sectors. Mrs. Laarakker joined Intravacc from cancer immunotherapy R&D company Gadeta, where she served as Chief Financial Officer and Managing Director since 2019. Nathalie began her professional career at PricewaterhouseCoopers, working for both the Amsterdam and the Boston (USA) offices. She qualified as a certified public accountant in 2001, after which she held various senior positions in several companies. Her previous positions include Head of Finance at the Nasdaq-listed biotech company Merus. She holds a Bachelor’s degree from the Amsterdam Business School and a post-doc degree from the University of Amsterdam.